Under the agreement, Vir will focus on discovering and engineering three dual-masked T-cell engager candidates, while Gilead secures the exclusive rights to advance these assets through clinical development, manufacturing, and commercialization. The partnership leverages Vir’s proprietary platform to direct the immune system’s T-cells toward specific solid tumor-associated antigens.
In section Market Quotes
Vir Biotechnology Rallies on $1.8 Billion Gilead Cancer Deal
Shares of Vir Biotechnology surged 8.2% to $11.48 Wednesday following a strategic collaboration with Gilead Sciences. The two firms will co-develop next-generation T-cell engagers, a specialized immunotherapy class designed to target solid tumors while navigating the toxicity hurdles that have historically hindered treatments for non-blood cancers.
The financial terms provide Vir with an immediate influx of $135 million, comprising a $65 million cash payment, a $25 million equity investment at a 30% premium, and $45 million in near-term preclinical milestones. Beyond these initial payments, the deal includes up to $1.74 billion in subsequent development and regulatory bonuses, alongside tiered royalties on future net sales.
Comments (0)
No comments yet. Be the first!